TruQuick™ HAV IgM

The TruQuick HAV IgM is a rapid chromatographic immunoassay for the qualitative detection of IgM antibody to Hepatitis A Virus (HAV) in serum or plasma.


Catalog No Size
Product Catalog No: TQ5225 Pack Size: 25 Tests

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Summary

HAV is a positive RNA virus, a unique member of picornavirdae1.Its transmission depends primarily on serial transmission from person to person by the fecal-oral route. Although hepatitis A is not ordinarily a sexually transmitted disease, the infection rate is high among male homosexuals, as result of oral-anal contact2,3. The presence of specific anti-HAV IgM in blood samples suggests acute or recent HAV infection 4-6. The IgM antibody rapidly increases in titer over a period of 4-6 weeks post infection, and then declines to non-detectable levels within 3 to 6 months in most patients 7. The TruQuick HAV IgM IgM is to be used to detect anti-HAV IgM in less than 20 minutes by untrained or minimally skilled personnel, without cumbersome laboratory equipment.

Test Procedure
  1. Remove the test cassette from sealed pouch and use it within one hour. Best results will be obtained if the assay is performed immediately after opening foil pouch.
  2. Hold the dropper vertically, draw the diluted specimen from sample dilution bottle upto the fill line marked on the dropper as shown in illustration below (approx.5L), transfer the diluted specimen to the sample area (S) which has been marked on the test cassette. Or use micropipette to add 5L diluted specimen into the sample area (S) which has been marked.
  3. Add 2 drops of buffer (approx. 80L) into the buffer well (B) marked on the test cassette, start the timer. See illustration below.
  4. Wait for the colored line(s) to appear. Read the result at 20 minutes, do not interpret the result after 30 minutes.
Order Enquiry

Order Enquiry Form

References
  1. Minor P. Picornaviridae. In: Francki RIB, Fauquet CM, Knudson DL, et al., eds. Classification and nomenclature of viruses (Arch Virol Supp 2). Wien: Springer-Verlag,1991: 320-326.
  2. Keeffe EB. Clinical approach to viral hepatitis in homosexual men. Med Clin North Am. 1986;70(3):567-86.
  3. Ballesteros J, Dal-Re R, Gonzalez A, del Romero J. Are homosexual males a risk group for hepatitis A infection in intermediate endemicity areas? Epidemiol Infect. 1996; 117(1):145-8.
  4. Bradley DW, Maynard JE, Hindman SH, et al: Serodiagnosis of viral hepatitis A: Detection of acute-phase immunoglobulin M anti-hepatitis A virus by radioimmunoassay. J Clin Microbiol 1977; 5: 521-530.
  5. Decker RH, Kosakowski SM, Vanderbilt AS, et al: Diagnosis of acute hepatitis A by HAVAB-M : A direct radioimmunoassay for IgM anti-HAV. Am J Clin Pathol 1981;76:140- 147.
  6. Locarnini SA, Ferris AA, Lehman NI, et al: The antibody response following hepatitis A infection. Intervirology 1974; 4:110-118.
  7. Skinhoj P, Mikkelsen F, Hollinger FB. Hepatitis A in Greenland: Importance of specific antibody testing in epidemiologic surveillance. Am J. Epidemiol 1977; 105: 104-147
Enquiry